Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alumis Inc. - Common Stock
(NQ:
ALMS
)
6.850
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alumis Inc. - Common Stock
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
January 06, 2026
Via
AB Newswire
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 06, 2026
From
Alumis Inc.
Via
GlobeNewswire
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
May 13, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
May 06, 2025
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 01, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
March 04, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
March 04, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
February 20, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
February 06, 2025
From
Halper Sadeh LLC
Via
Business Wire
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Alumis to Participate in Upcoming September Investor Conferences
September 03, 2024
From
Alumis Inc.
Via
GlobeNewswire
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
August 13, 2024
From
Alumis Inc.
Via
GlobeNewswire
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
July 29, 2024
From
Alumis Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
